Giovanni Antonio Martinelli
Dr. Giovanni Antonio Martinelli is an oncohematologist at Casa di Cura La Madonnina.
In 1974 he graduated from the Faculty of Medicine and Surgery of the University of Siena, where in 1977 he also received a specialization in diseases of the cardiovascular system. In 1980, he received a degree in oncology at the University of Ferrara.
From 1984 to 1995, he worked as an assistant in the Department of Hematology at IOSI in Bellinzona. In 1999, he completed an internship at the Department of Medical Oncology at the Finsen Institute in Copenhagen. From 1997 to 2014, he held the position of Head of the Department of Oncohematology at the European Institute of Oncology in Milan.
For many years, he has been engaged in the diagnosis and treatment of all oncological diseases, especially lung cancer. During his time as the head of the inpatient department of the Oncogematology Department of the Oncological Institute of Switzerland, he deepened his interest in oncogematological diseases such as leukemias, lymphomas and myelomas.
Upon returning to Italy, he is engaged in hematology by treating patients with leukemic, lymphoproliferative and myeloma diseases. In particular, the establishment of the Department of Oncohematology at the European Cancer Institute (IEO). During his 20 years at IEO, he has performed more than 2,000 autologous transplantation procedures and more than 120 allogeneic transplants.
Dr. Martinelli provides oncogematological consultations at Casa di Cura La Madonnina through outpatient consultations, treatment and diagnosis in the conditions of hospitalization. He pays special attention to the therapeutic approach, always promoting more conservative methods of treatment that respect the quality of life of patients, through less aggressive, but equally effective and effective methods of treatment.
In the field of research, he is particularly interested in new therapeutic strategies in the field of malignant lymphomas, where he actively participated in the development of antibiotic therapy for Helicobacter Pylori positive marginal gastric lymphoma and in the use of monoclonal antibodies against CD-20 in follicular lymphomas, as well as marginal and mantle cell.
He participated in joint clinical research groups such as SAKK, EBMT, GIMEMA, EORTC, promoting clinical research in the field of hematology. As a result, he has more than 200 publications in the field of medicine with articles published in the most authoritative medical journals.